Loading...

Spero Therapeutics

DB:2HA
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2HA
DB
$204M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Spero Therapeutics has significant price volatility in the past 3 months.
2HA Share Price and Events
7 Day Returns
-13.9%
DB:2HA
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-
DB:2HA
-9.2%
DE Biotechs
-6.7%
DE Market
2HA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Spero Therapeutics (2HA) -13.9% -8.6% 43.4% - - -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • No trading data on 2HA.
  • No trading data on 2HA.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Spero Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Spero Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €10.212.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Spero Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Spero Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2HA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.60
NasdaqGS:SPRO Share Price ** NasdaqGS (2019-04-18) in USD $11.85
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Spero Therapeutics.

DB:2HA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SPRO Share Price ÷ EPS (both in USD)

= 11.85 ÷ -2.60

-4.55x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spero Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Spero Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Spero Therapeutics's expected growth come at a high price?
Raw Data
DB:2HA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.55x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
9.2%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Spero Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Spero Therapeutics's assets?
Raw Data
DB:2HA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $6.71
NasdaqGS:SPRO Share Price * NasdaqGS (2019-04-18) in USD $11.85
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:2HA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SPRO Share Price ÷ Book Value per Share (both in USD)

= 11.85 ÷ 6.71

1.77x

* Primary Listing of Spero Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spero Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Spero Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Spero Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Spero Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Spero Therapeutics expected to grow at an attractive rate?
  • Spero Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Spero Therapeutics's earnings growth is positive but not above the Germany market average.
  • Spero Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:2HA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2HA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 9.2%
DB:2HA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 62.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2HA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2HA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 204 18 47 4
2022-12-31 63 -95 -68 4
2021-12-31 21 -96 -88 3
2020-12-31 11 -85 -83 4
2019-12-31 12 -81 -64 4
DB:2HA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 4 -40 -42
2018-09-30 3 -39 -46
2018-06-30 3 -44 -47
2018-03-31 3 -44 -50
2017-12-31 2 -39 -46
2017-09-30 1 -36 -40
2017-06-30 1 -32 -35
2017-03-31 0 -29 -30
2016-12-31 0 -29 -30

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Spero Therapeutics's earnings are expected to grow by 9.2% yearly, however this is not considered high growth (20% yearly).
  • Spero Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2HA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Spero Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2HA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.05 2.72 1.38 2.00
2022-12-31 -2.81 -2.17 -3.94 3.00
2021-12-31 -3.94 -3.47 -4.22 3.00
2020-12-31 -3.50 -2.35 -4.37 4.00
2019-12-31 -3.32 -2.80 -3.94 4.00
DB:2HA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.60
2018-09-30 -3.30
2018-06-30 -4.94
2018-03-31 -8.14
2017-12-31 -17.82
2017-09-30 -119.70
2017-06-30 -106.91
2017-03-31 -93.90
2016-12-31 -95.87

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Spero Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Spero Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Spero Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Spero Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Spero Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Spero Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Spero Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Spero Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Spero Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Spero Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2HA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 3.97 -41.66 12.89
2018-09-30 3.27 -45.83 11.73
2018-06-30 3.21 -47.45 12.25
2018-03-31 2.99 -49.61 12.14
2017-12-31 1.98 -46.10 10.84
2017-09-30 1.32 -39.66 10.57
2017-06-30 0.72 -34.99 8.82 -13.40
2017-03-31 0.48 -29.97 7.42 -6.70
2016-12-31 0.34 -29.93 7.22
2015-12-31 -13.43 2.20

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Spero Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Spero Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Spero Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Spero Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Spero Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Spero Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Spero Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Spero Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Spero Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Spero Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Spero Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Spero Therapeutics Company Filings, last reported 3 months ago.

DB:2HA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 115.86 0.00 115.44
2018-09-30 125.55 0.00 131.23
2018-06-30 65.67 0.00 66.64
2018-03-31 74.90 0.00 75.39
2017-12-31 84.96 0.00 87.29
2017-09-30 24.28 0.00 25.37
2017-06-30 33.26 0.00 36.30
2017-03-31 6.36 0.00 10.32
2016-12-31 6.36 0.00 10.32
2015-12-31 -0.26 0.00 5.69
  • Spero Therapeutics has no debt.
  • Spero Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Spero Therapeutics has sufficient cash runway for 2.7 years based on current free cash flow.
  • Spero Therapeutics has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 30.1% each year.
X
Financial health checks
We assess Spero Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Spero Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Spero Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Spero Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Spero Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Spero Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Spero Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2HA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2HA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Spero Therapeutics has not reported any payouts.
  • Unable to verify if Spero Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Spero Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Spero Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Spero Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Spero Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Spero Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Spero Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Spero Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ankit Mahadevia
COMPENSATION $3,184,277
AGE 37
TENURE AS CEO 4.1 years
CEO Bio

Mr. Ankit Mahadevia, MD, MBA serves as the Chief Executive Officer and President of Spero Therapeutics, LLC. Mr. Mahadevia Co-founded of Spero Therapeutics, Inc. in 2013 and has been its Chief Executive Officer and President since March 2015. He serves as an Atlas Advisor at Atlas Venture L.P. He co-founded Synlogic, Inc. and served as its President. He served as Entrepreneur-In-Residence at Atlas Venture L.P. Mr. Mahadevia joined Atlas Venture in 2008 and focused on other medical technologies that met a significant unmet clinical need. He also served as a Principal at Atlas Venture. He served as Acting CBO at Spero Therapeutics, Inc. He serves as the Chief Business Officer of Rodin Therapeutics Inc. He is also actively involved in the Shire/Atlas Venture Alliance and the Atlas/Monsanto Seed Fund Alliance. Mr. Mahadevia was a Venture Partner in the life sciences group at Atlas Venture in Cambridge, Massachusetts, where he supported the formation of eight companies focused on novel drug discovery platforms and therapeutic products, including Synlogic Therapeutics and Translate Bio. He has led three of these companies as acting or full-time CEO. He works closely with Arteaus Therapeutics and JenaValve. He worked with Sirion Therapeutics. Prior to joining Atlas Venture in 2008, Mr. Mahadevia worked on product and business development with the founding team at Arcion Therapeutics, Inc. Before that, he held positions in Business Development at Genentech, Inc. and Vanda Pharmaceuticals, Inc. Mr. Mahadevia also served clients in the health services sector at McKinsey & Company, Inc. He also served as a Consultant at Monitor Group, where he supported clients in the biotechnology and medical device industries on strategy, marketing and business development. Mr. Mahadevia held roles in the U.S. Government Accountability Office. He has been a Director at Spero Therapeutics, Inc. since September 2013. He serves as a Director of Annovation Biopharma and Fibrex Medical Research & Development GesmbH. He serves as a Board Observer at Resolvyx Pharmaceuticals and Nimbus Discovery. He served as a Director of Lumavita AG. He served as Director at Synlogic, Inc. since July 22, 2014 until July 18, 2016. He served as a Director of RaNA Therapeutics, Inc. (now known as Translate Bio, Inc.). He is a Reviewer for the National Cancer Institute SBIR Bridge Awards. He also serves on the board of the Johns Hopkins Technology Alliance/Johns Hopkins Alliance for Technology Transfer. Dr. Mahadevia began his career in health care policy, with roles in the U.S. Senate Health, Education, Labor and the Mexican Institute of Social Security. He served as a Board Observer at Molecular Biometrics, Inc. He was appointed by the U.S. Secretary of Health and Human Services to the Advisory Council of the NIH Center for Advancing Translational Sciences. During his medical training, he published research in glaucoma therapy and neurovascular interventions. Mr. Mahadevia completed his M.D. from Johns Hopkins University School of Medicine and his M.B.A. from the Wharton School at the University of Pennsylvania. He graduated summa cum laude with a B.A. in Economics and Biology from Northwestern University.

CEO Compensation
  • Ankit's compensation has increased whilst company is loss making.
  • Ankit's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Spero Therapeutics management team in years:

1.3
Average Tenure
50.5
Average Age
  • The average tenure for the Spero Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Ankit Mahadevia

TITLE
Co-Founder
COMPENSATION
$3M
AGE
37
TENURE
4.1 yrs

Joel Sendek

TITLE
CFO & Treasurer
COMPENSATION
$1M
AGE
51
TENURE
1.9 yrs

Cristina Larkin

TITLE
Chief Operating Officer
COMPENSATION
$1M
AGE
48
TENURE
1.6 yrs

Tom Parr

TITLE
Chief Scientific Officer
COMPENSATION
$451K
AGE
64
TENURE
5 yrs

Sharon Klahre

TITLE
Director of Investor Relations

Jay Blackington

TITLE
Head of People Strategy & Culture
TENURE
0.4 yrs

Tim Keutzer

TITLE
Senior Vice President of Development
AGE
50
TENURE
1.3 yrs

David Melnick

TITLE
Chief Medical Officer
AGE
66
TENURE
1.3 yrs

Ian Critchley

TITLE
Head of Clinical Microbiology
TENURE
1 yrs

Susannah Walpole

TITLE
Head of Clinical Operations
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Spero Therapeutics board of directors in years:

4.9
Average Tenure
61
Average Age
  • The tenure for the Spero Therapeutics board of directors is about average.
Board of Directors

Milind Deshpande

TITLE
Chairman
COMPENSATION
$199K
AGE
61

Ankit Mahadevia

TITLE
Co-Founder
COMPENSATION
$3M
AGE
37
TENURE
5.6 yrs

Frank Thomas

TITLE
Director
COMPENSATION
$139K
AGE
48
TENURE
1.8 yrs

Patrick Vink

TITLE
Director
COMPENSATION
$140K
AGE
55
TENURE
3.6 yrs

Jean-François Formela

TITLE
Director
COMPENSATION
$7K
AGE
61
TENURE
6.1 yrs

Paul Ambrose

TITLE
Clinical Advisor
TENURE
4.9 yrs

Gordon Archer

TITLE
Clinical Advisor
AGE
74
TENURE
4.9 yrs

George Drusano

TITLE
Clinical Advisor
TENURE
4.9 yrs

Eric Gordon

TITLE
Scientific Advisors
TENURE
4.9 yrs

Steve Gilman

TITLE
Scientific Advisor
AGE
65
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
17. Jul 18 Buy GlaxoSmithKline plc Company 17. Jul 18 17. Jul 18 80,000 €10.69 €855,500
X
Management checks
We assess Spero Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Spero Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Details
Name: Spero Therapeutics, Inc.
2HA
Exchange: DB
Founded: 2013
$181,486,687
17,215,976
Website: http://sperotherapeutics.com
Address: Spero Therapeutics, Inc.
675 Massachusetts Avenue,
14th Floor,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SPRO Common Stock Nasdaq Global Select US USD 02. Nov 2017
DB 2HA Common Stock Deutsche Boerse AG DE EUR 02. Nov 2017
Number of employees
Current staff
Staff numbers
41
Spero Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:49
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.